Starpharma Holdings Limited

SPL.ASX

Health Care

Biotechnology - development of dendrimer technology for pharmaceutical, life science and other applications.

Market Data

Price

$0.715

+0.0%

Market Cap

$294.6M

P/E Ratio

-100000.0x

EPS

$-0.008

Div. Yield

0.00%

52-Week Change

+0.6%

Recent Announcements

15 Apr 2026 Sph Neutral

Becoming a substantial holder

Rhuron Pty Ltd became a substantial holder of Starpharma Holdings Limited on 13 April 2026, acquiring 40,050,000 ordinary shares (9.52% voting power) through various shareholding recall transactions from a prime broker for cash consideration of $12,195,074.

12 Mar 2026 Sph Neutral

Ceasing to be a substantial holder

UBS Group AG ceased to be a substantial holder.

18 Feb 2026 Sph Neutral

Ceasing to be a substantial holder

UIL Limited (and associates as listed in Annexure B) ceased to be a substantial holder.

10 Feb 2026 Sph Neutral

Ceasing to be a substantial holder

Robmar Investments Pty Limited has ceased to be a substantial holder in Starpharma Holdings Limited as of February 10, 2026, filing a Form 605 notice with the Australian Stock Exchange.

Get real-time alerts for SPL

Receive AI-powered earnings summaries and instant notifications when Starpharma Holdings Limited releases results.